This evidence-based guidance was developed by the HPA Primary Care Unit and GP Microbiology Laboratory Use Group, in collaboration with GPs, the AMM and other experts. It is in line with HPA SOPs, Clinical Knowledge Summaries & SIGN.


For Review October 2009
References


7. Delaney BC, Qume M, Moayyedi P, Logan RFA, Ford AC, Elliott C, McNulty C, Wilson S, Hobbs FDR. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008;336:651-4. Test and treat and acid suppression are equally cost-effective in the initial management of dyspepsia. Empirical acid suppression is an appropriate initial strategy. As costs are similar overall, general practitioners should discuss with patients at which point to consider H. pylori testing.


15. Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. GUT 2001;48:287-9. Data from 8 studies of near patient serology tests show sensitivity 71.5% and specificity 87.6% and urea breath test has 95% specificity and sensitivity.


Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, Delaney B. Systematic review and economic evaluation of *Helicobacter pylori* eradication treatment for non-ulcer dyspepsia. *BMJ* 2000;321:649-64. This is a systematic review of economic evaluation of HP eradication in non-ulcer dyspepsia. The mean response rate to treatment in HP positive NUD patients is 36% and the mean placebo response rate is 28%.

Gene E, Calvet X, Azagra R. Diagnosis of *Helicobacter pylori* after triple therapy in uncomplicated duodenal ulcer: a cost-effective analysis. *Aliment Pharmacol Ther* 2000;14:433-42. Comparison of different follow-up strategies post treatment – in patients with uncomplicated DU (and therefore we may assume NUD) testing for eradication after HP treatment markedly increases cost with no clear improvement in results.

Diagnostic and Specialist Identification Unit, Gastrointestinal, Emerging and Zoonotic Infections, Health Protection Agency Centre for Infections, 61 Colindale Avenue, Colindale, London NW9 5EQ. Tel: 020 8327 6114.

http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947328906

We welcome, in fact encourage, opinions on the advice given and future topics we should cover. We would be most appreciative if you could email any evidence or references that support your requests for change so that we may consider them at our annual review.

Comments should be submitted to Dr Cliodna McNulty, Head, HPA Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN.

Email: cliodna.mcnulty@hpa.org.uk or jill.whiting@hpa.org.uk